Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Diamedica Therapeutics Inc
(NQ:
DMAC
)
2.400
+0.050 (+2.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Diamedica Therapeutics Inc
< Previous
1
2
3
Next >
DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations
September 14, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Present at Lake Street’s 6th Annual Best Ideas Growth Conference
September 06, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results
August 10, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022
August 04, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022
August 01, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199
July 06, 2022
From
DiaMedica Therapeutics
Via
Business Wire
DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022
May 25, 2022
From
DiaMedica Therapeutics
Via
Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results
May 04, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022
April 28, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results
March 14, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer
February 02, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Present Research at International Stroke Conference
January 25, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer
January 05, 2022
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access Event
December 13, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 17, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial Results
November 10, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021
November 09, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial
November 08, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021
November 04, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021
October 18, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke
September 30, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Closing of $30 Million Private Placement
September 28, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces $30 Million Private Placement
September 27, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke
September 13, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Participate at Upcoming Investor Conferences
September 07, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results
August 11, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results and Provide a Business Update August 12, 2021
August 05, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
July 28, 2021
From
DiaMedica Therapeutics
Via
Business Wire
DiaMedica Therapeutics Elects Two Industry Veterans to Its Board of Directors
July 15, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD
June 29, 2021
From
DiaMedica Therapeutics Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.